Mesenchymal stem cells control alloreactive CD8+CD28- T cells

Clinical and Experimental Immunology

Volumn 174, Issue 3, 2013, Pages 449-458

  Engela, A U ^a   Baan, C C ^a   Litjens, N H R ^a   Franquesa, M ^a   Betjes, M G H ^a   Weimar, W ^a   Hoogduijn, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CD8 T cells; Co stimulation co stimulatory molecules; Immune regulation; Stem cells

Indexed keywords

BELATACEPT; CD28 ANTIGEN; GAMMA INTERFERON; GRANZYME B; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CD8 T CELLS; CO-STIMULATION/CO-STIMULATORY MOLECULES; IMMUNE REGULATION; STEM CELLS;

ANTIGENS, CD28; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; GRANZYMES; HUMANS; IMMUNOCONJUGATES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MESENCHYMAL STROMAL CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886264837     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12199     Document Type: Article

References (68)

1. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229:307-321.
2. Wekerle T, Grinyo JM. Belatacept: from rational design to clinical application. Transpl Int 2012; 25:139-150.
3. Jennings C, Rich K, Siegel JN, Landay A. A phenotypic study of CD8+ lymphocyte subsets in infants using three-color flow cytometry. Clin Immunol Immunopathol 1994; 71:8-13.
4. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005; 205:158-169.
5. Fagnoni FF, Vescovini R, Mazzola M etal. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 1996; 88:501-507.
6. Hooper M, Kallas EG, Coffin D, Campbell D, Evans TG, Looney RJ. Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis. J Rheumatol 1999; 26:1452-1457.
7. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003; 52:599-607.
8. Serrano D, Monteiro J, Allen SL etal. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997; 158:1482-1489.
9. Wang EC, Lawson TM, Vedhara K, Moss PA, Lehner PJ, Borysiewicz LK. CD8high+ (CD57+) T cells in patients with rheumatoid arthritis. Arthritis Rheum 1997; 40:237-248.
10. Mikulkova Z, Praksova P, Stourac P etal. Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol 2010; 262:75-79.
11. Bartholomew A, Sturgeon C, Siatskas M etal. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
12. Hoogduijn MJ, Crop MJ, Peeters AM etal. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16:597-604.
13. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann NY Acad Sci 2012; 1266:107-117.
14. Le Blanc K, Frassoni F, Ball L etal. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
15. Perico N, Casiraghi F, Introna M etal. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
16. Reinders ME, de Fijter JW, Roelofs H etal. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2:107-111.
17. Crop MJ, Baan CC, Korevaar SS etal. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87:896-906.
18. Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant 2012; 17:55-62.
19. Meijers RW, Litjens NH, de Wit EA etal. Cytomegalovirus contributes partly to uraemia-associated premature immunological ageing of the T cell compartment. Clin Exp Immunol 2013; doi: 10.1111/cei.12188.
20. Kim WR, Stock PG, Smith JM etal. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 2013; 13 (Suppl. 1):73-102.
21. Matas AJ, Smith JM, Skeans MA etal. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 2013; 13 (Suppl. 1):11-46.
22. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71:SS42-51.
23. Vincenti F, Charpentier B, Vanrenterghem Y etal. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
24. Durrbach A, Pestana JM, Pearson T etal. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
25. Vincenti F, Larsen CP, Alberu J etal. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
26. (null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 2011; 166:94-102.
27. Eylar EH, Lefranc CE, Yamamura Y etal. HIV infection and aging: enhanced interferon- and tumor necrosis factor-alpha production by the CD8+ CD28- T subset. BMC Immunol 2001; 2:10.
28. Bandres E, Merino J, Vazquez B etal. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol 2000; 96:230-235.
29. Sun Z, Zhong W, Lu X etal. Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells. J Clin Immunol 2008; 28:464-472.
30. Chiu WK, Fann M, Weng NP. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol 2006; 177:7802-7810.
31. Chong LK, Aicheler RJ, Llewellyn-Lacey S, Tomasec P, Brennan P, Wang EC. Proliferation and interleukin 5 production by CD8hi CD57+ T cells. Eur J Immunol 2008; 38:995-1000.
32. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150:1147-1159.
33. Borthwick NJ, Bofill M, Gombert WM etal. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS 1994; 8:431-441.
34. Plunkett FJ, Franzese O, Finney HM etal. The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 2007; 178:7710-7719.
35. Latchman Y, Wood CR, Chernova T etal. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-268.
36. Freeman GJ, Long AJ, Iwai Y etal. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-1034.
37. Meijers RW, Litjens NH, de Wit EA etal. Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. Immun Ageing 2012; 9:19.
38. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-1369.
39. Tseng SY, Otsuji M, Gorski K etal. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193:839-846.
40. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011; 134:17-32.
41. Fiorentino S, Dalod M, Olive D, Guillet JG, Gomard E. Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol 1996; 70:2022-2026.
42. Schirmer M, Goldberger C, Wurzner R etal. Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis. Arthritis Res 2002; 4:71-76.
43. Hamzaoui A, Chaouch N, Grairi H, Ammar J, Hamzaoui K. Inflammatory process of CD8+ CD28- T cells in induced sputum from asthmatic patients. Mediators Inflamm 2005; 2005:160-166.
44. Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 1998; 10:775-783.
45. Scotto L, Naiyer AJ, Galluzzo S etal. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol 2004; 65:1297-1306.
46. Filaci G, Fenoglio D, Fravega M etal. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179:4323-4334.
47. Lin YX, Wang LL, Yan LN etal. Analysis of CD8+CD28- T-suppressor cells in living donor liver transplant recipients. Hepatobiliary Pancreat Dis Int 2009; 8:241-246.
48. Betjes MG, Meijers RW, de Wit EA, Weimar W, Litjens NH. Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection. Transplantation 2012; 94:63-69.
49. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29:848-862.
50. Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996; 156:3587-3590.
51. Vaziri H, Schachter F, Uchida I etal. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993; 52:661-667.
52. Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 2002; 105:117-125.
53. Vallejo AN, Nestel AR, Schirmer M, Weyand CM, Goronzy JJ. Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity. J Biol Chem 1998; 273:8119-8129.
54. Vallejo AN, Weyand CM, Goronzy JJ. Functional disruption of the CD28 gene transcriptional initiator in senescent T cells. J Biol Chem 2001; 276:2565-2570.
55. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 2003; 101:3543-3549.
56. D'Andrea A, Rengaraju M, Valiante NM etal. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176:1387-1398.
57. Mazar J, Thomas M, Bezrukov L etal. Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. J Biol Chem 2009; 284:22022-22028.
58. Augello A, Tasso R, Negrini SM etal. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35:1482-1490.
59. Hoogduijn MJ, Crop MJ, Korevaar SS etal. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008; 86:1283-1291.
60. Buron F, Perrin H, Malcus C etal. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc 2009; 41:3347-3352.
61. Franquesa M, Baan CC, Korevaar SS etal. The effect of rabbit antithymocyte globulin on human mesenchymal stem cells. Transpl Int 2013; 26:651-658.
62. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75:389-397.
63. Engela AU, Hoogduijn MJ, Boer K etal. Human adipose-tissue derived mesenchymal stem cells induce functional de novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol 2013; 173:343-354.
64. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008; 181:2285-2291.
65. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 2013; 123:580-593.
66. Wing K, Onishi Y, Prieto-Martin P etal. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.
67. Charbonnier LM, Vokaer B, Lemaitre PH, Field KA, Leo O, Le Moine A. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transplant 2012; 12:2313-2321.
68. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L etal. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31:588-595.